SRPT vs. ANF

In the year-to-date period, SRPT achieves a -6.47% return, which is significantly higher than ANF's -20.13% return. Over the past 10 years, SRPT has outperformed ANF with an annualized return of 24.45%, while ANF has yielded a comparatively lower 19.35% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Sarepta Therapeutics, Inc. (SRPT) and Abercrombie & Fitch Co. (ANF). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current SRPT Sharpe Ratio is -0.09, which is lower than the ANF Sharpe Ratio of 0.22. The chart below compares the historical Sharpe Ratios of SRPT and ANF, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither SRPT nor ANF has paid dividends to shareholders.

The maximum SRPT drawdown since its inception was -98.17%, which is greater than ANF's maximum drawdown of -86.59%. Use the drawdown chart below to compare losses from any high point for SRPT and ANF. For additional features, visit the drawdowns tool.

The current volatility for Sarepta Therapeutics, Inc. (SRPT) is 8.43%, while Abercrombie & Fitch Co. (ANF) has a volatility of 20.46%. This indicates that SRPT experiences smaller price fluctuations and is considered to be less risky than ANF based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Sarepta Therapeutics, Inc. and Abercrombie & Fitch Co.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.